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Current Status of Antimicrobial 
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While some trends in antimicrobial resistance rates are universal, others appear to be unique for specific
regions. In Taiwan, the strikingly high prevalence of resistance to macrolides and streptogramin in clinical
isolates of gram-positive bacteria correlates with the widespread use of these agents in the medical and
farming communities, respectively. The relatively low rate of enterococci that are resistant to glycopeptide
does not parallel the high use of glycopeptides and extended-spectrum beta-lactams in hospitals. The
evolving problem of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneu-
moniae isolates is substantial, and some unique enzymes have been found. Recently, some gram-nega-
tive bacteria (e.g., Pseudomonas aeruginosa and Acinetobacter baumannii) that are resistant to all
available antimicrobial agents including carbapenems have emerged. 
ntimicrobial resistance has become a major health prob-
lem worldwide, affecting every country to some degree.
It is an inevitable consequence of the inappropriate use of anti-
biotics in humans and animals. In Europe and North America,
methicillin-resistant Staphylococcus aureus (MRSA), penicil-
lin-nonsusceptible Streptococcus pneumoniae (PNSSP), van-
comycin-resistant enterococci (VRE), and extended-spectrum
beta-lactamase (ESBL)-producing Enterobacteriaceae have
emerged and spread into communities and hospitals. In Tai-
wan, the widespread use of antimicrobial agents in primary
care clinics and animal husbandry has allowed the rapid emer-
gence of resistant bacteria. During the last 2 decades, many
antimicrobial agents—such as extended-spectrum cepha-
losporins, carbapenems, fluoroquinolones, and aminoglyco-
sides—have been introduced and empirically used as first-line
drugs to treat these resistant bacteria (1,2). This has further
accelerated the development and dissemination of drug-resis-
tant bacteria. Previous studies in Taiwan have clearly demon-
strated the remarkably high prevalence of some critically
resistant bacteria, such as MRSA, PNSSP, and macrolide-
resistant streptococci (1,2). In addition, several multidrug-
resistant bacteria, including ones resistant to carbapenems and
fluoroquinolones and pan-drug-resistant gram-negative bacilli,
have been isolated from different hospitals (3-6). 
Approval of Antibiotics
Table 1 shows the years that selected antibiotics were
approved in Taiwan. These antibiotics are now widely used to
treat various infections, including community-acquired and
nosocomial infections. Until now, two gylcopeptides (vanco-
mycin and teicoplanin), two carbapenems (imipenem and
meropenem), four macrolides (erythromycin, roxithromycin,
clarithromycin, and azithromycin), and six quinolones (nalid-
ixic acid, norfloxacin, ofloxacin, lomefloxacin, ciprofloxacin,
and levofloxacin) have been available for clinical use in Tai-
wan. Most of these drugs were also readily available at drug-
stores without prescription before 1995.
Drug-Resistant Bacteria
The following drug-resistance data were collected from a
nationwide resistance survey (Surveillance from Multicenter
Antimicrobial Resistance in Taiwan) of clinical isolates
(including those recovered from hospitals and outpatients)
from 12 major hospitals as well as isolates causing nosocomial
infections from National Taiwan University Hospital (NTUH)
in 2000 in Taiwan. These hospitals are located in different
parts of the country. The number of beds in these hospitals
ranged from 800 to 3,200. All these data were derived by using
the disk-diffusion method (7). 
Some dilution antimicrobial susceptibility and epidemiol-
ogy studies, including >100 strains published in English-lan-
guage journals from January 1995 through 2001, were also
included. Rather than provide a comprehensive review of all
resistance problems in Taiwan, our aim was to point out some
of the more critical resistance problems threatening the treat-
ment of infections caused by Staphylococcus species, S. pyo-
genes, Streptococcus pneumoniae, Enterococcus species, and
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Table 1. Year of approval of selected antimicrobial agents in Taiwan
Antimicrobial agent Year of approval
Erythromycin 1968
Oxacillin 1970
Gentamicin 1981
Cefotaxime 1983
Amikacin 1986
Ceftazidime 1988
Imipenem 1988
Vancomycin 1983
Ciprofloxacin 1990
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Mycobacterium tuberculosis among the gram-positive patho-
gens, and Haemophilus influenzae,  Escherichia coli, Kleb-
siella pneumoniae, Enterobacter species, Salmonella species,
Campylobacter species, Pseudomonas aeruginosa, and Acine-
tobacter baumannii among the gram-negative pathogens.
Resistance rates included in this review reflect both intermedi-
ate and fully resistant populations. Table 2 summarizes the
prevalence of antimicrobial resistance among clinical isolates
(12 hospitals, including NTUH) and nosocomial isolates (from
NTUH only) of some selected bacterial species. The ranges in
numbers of clinical isolates of select bacteria (Table 2) recov-
ered from these hospitals were as follows: Staphylococcus
aureus, 1,889 to 7,516 isolates; beta-hemolytic streptococci,
335 to 1,102; S. pneumoniae, 138 to 461; enterococci, 509 to
3,676; H. influenzae, 427 to 602; E. coli, 1,734 to 9,553; K.
pneumoniae, 950 to 3,226; E. cloacae, 427 to 1,426; nonty-
phoid Salmonella, 94 to 626; P. aeruginosa, 1,741 to 4,896;
and A. baumannii, 896 to 2,434.
Gram-Positive Bacteria 
MRSA
MRSA was first documented in Taiwan in the early 1980s
(8). Since then, there has been a remarkable increase in preva-
lence of MRSA in nosocomial infections (from 26.7% in 1990
to 75% to 84% in 1998-2000) (9). Several dominant clones
have been documented in hospitals (9). The prevalence of
MRSA in community-acquired infections remains unclear,
although the incidence of MRSA among patients of outpatient
departments is estimated to be 40% (1). Data from a survey of
>5,000 clinical isolates of S. aureus at the NTUH from Janu-
ary 1999 to June 2001 using brain-heart-infusion agar plus 4
mg/L of vancomycin showed results negative for vancomycin-
intermediate or -resistant strains.
PNSSP and Multidrug-Resistant Streptococcus 
pneumoniae (MDRSP)
The overall prevalence of clinical isolates of PNSSP in
1999-2000 was 60% to 80%, including 20% to 30% penicillin-
intermediate and 40% to 50% penicillin-resistant strains (10-
16). This prevalence of PNSSP was slightly lower than that in
Korea and higher than that in most other geographic areas
(15,16). All PNSSP were resistant to multiple antibiotics
(13,16). This resistance was higher among nasopharyngeal
isolates from children (12). Approximately 60% of the PNSSP
isolates were also not susceptible to extended-spectrum cepha-
losporins and carbapenems (13). Most of these PNSSP belong
to serotypes 23F, 19F, 6B, and 14 (13,15). Wide dissemination
of multiple high-level penicillin-, extended-spectrum cepha-
losporin-, and macrolide-resistant clones as well as the Spain
23F clone contributes to the high rates of resistance to these
drugs in clinical isolates of S. pneumoniae (14,17). Only one
clinical isolate was reported to be resistant to fluoroquinolones
(18). 
VRE and Glycopeptide-Resistant Staphylococci
The first clinical isolate of Van-A-phenotype VRE (E.
faecalis) was found in 1995 (19). Since then, isolation of VRE
remains rare and accounts for <3% of all clinical isolates of
enterococci (20,21). The proportion of Enterococcus hospital
isolates resistant to vancomycin in Taiwan is low compared
with those in North America and Europe (22), a finding that
needs further investigation. However, an increase in VRE
Table 2. Prevalence of antimicrobial resistance in selected bacteria 
(all clinical isolates) isolated from 12 major hospitals, including 
National Taiwan University Hospital (NTUH), in Taiwan in 2000 and 
in all clinical isolates and isolates causing nosocomial infections 
from NTUH in 2000a
% of isolates
2,000 
(12 hospitals)
(clinical)
2,000
(NTUH)
(clinical/nosoco-
mial) Resistant pathogen
Methicillin-resistant Staphylo-
coccus  aureus
53-83 65/74
Erythromycin-resistant beta-
hemolytic streptococci
30-51 34/−
Penicillin-nonsusceptible Strep-
tococcus pneumoniae
60-84 77/−
Erythromycin-resistant S. pneu-
moniae
67-100 89/−
Gentamicin-resistant (high-
level) enterococci
36-54 48/54
Vancomycin-resistant entero-
cocci
1-3 3/2
Ampicillin-resistant H. influen-
zae
45-73 61/−
Cefotaxime-resistant Escheri-
chia coli
5-19 12/19
Ciprofloxacin-resistant E. coli 11-33 20/29
Cefotaxime-resistant Kleb-
siella pneumoniae
4-34  9/18
Ciprofloxacin-resistant K. 
pneumoniae
5-33 9/16
Cefotaxime-resistant E. cloacae 36-68 45/49
Ampicillin-resistant non-
typhoid Salmonella
44-69 56/−
Cefotaxime-resistant non- 
typhoid Salmonella
1-4 2/−
Quinolone resistant non-typhi 
Salmonella
0-16 0/−
Ceftazidime-resistant 
Pseudomonas aeruginosa
4-21 13/10
Imipenem-resistant P. aerugi-
nosa
3-16 14/10
Ciprofloxacin-resistant P. 
aeruginosa
10-36 15/10
Imipenem-resistant Acineto-
bacter baumannii
0-19 19/16
Ciprofloxacin-resistant A. bau-
mannii
54-74 54/42
aSusceptibility of these bacteria was determined by the standard disk-diffusion 
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isolation associated with the continuous widespread use of
glycopeptides in a Taiwanese university hospital was observed
(23). Furthermore, interhospital and nosocomial spread of
some VRE clones, particularly one vanB2 E. faecium clone, or
long-term persistence of multiple clones in hospitalized
patients still exists (21,24). Although avoparcin has been
approved for veterinary use since 1977, this agent has been
banned in the farming industry since 2000 (24). Glycopeptide
resistance has been found in some isolates of coagulase-negative
staphylococci, particularly in S. simulans and S. warneri (25).
Macrolide-Resistant Streptococci
Under the increasing and highly selective pressure of mac-
rolide usage in Taiwan, the prevalence of macrolide resistance
and distribution of M-phenotype (mef gene-positive) among
macrolide-resistant isolates vary among different streptococcal
species (Figure) (26-31). More than 90% of the S. pneumoniae
isolates were resistant to macrolides, and approximately two
thirds exhibited high-level resistance (MLSB phenotype-erm
gene-positive) (29). However, macrolide resistance accounted
for 50% to 60% of all clinical isolates of S. pyogenes, and a
stepwise increase of proportion of M phenotype was clearly
demonstrated (29). 
Streptogramin-Resistant Gram-Positive Cocci
Quinupristin-dalfopristin is not available for clinical use in
Taiwan; nevertheless, the incidence of resistance to this agent
was high (51%) in vancomycin-resistant E. faecium (25).
Three resistant E. faecium isolates were recovered from animal
sources (pigs) in Taiwan. Restricted use of virginiamycin,
which has been widely used in animal feed for >20 years in
this country, might be required to alleviate quinupristin-dalfo-
pristin resistance among bacteria from human sources (25). 
Multidrug-Resistant Mycobacterium tuberculosis 
(MDRTB)
The prevalence of pulmonary tuberculosis (TB) in adults
was 0.65% in 1993, and the associated death rate was 6.93 per
100,000 in 1998 (32). The overall incidence of isoniazid-resis-
tant  M. tuberculosis was 31.5%. The incidence of primary
resistance (isolates from patients with newly diagnosed TB
who had no prior history of anti-TB therapy or from patients
whose anti-TB therapy was begun <2 weeks) was 12.0%; the
incidence of acquired resistance (isolates from patients who
had a prior history of anti-TB medication) was 63.0%. The
overall incidence of MDRTB was 17.3% (primary resistance
1.6%; acquired resistance 46%) (33). An aggressive interven-
tion program, such as expanded use of directly observed ther-
apy, short course, is ongoing to improve the cure rate of TB
and to decrease the resistance rate.
Gram-Negative Bacilli 
H. influenzae and Moraxella catarrhalis
The annual incidence of invasive H. influenzae type b dis-
ease in children <5 years old was 1.6 to 1.9 per 100,000 popu-
lation per year before the introduction of conjugated Hib
vaccine in 1995 (34). Beta-lactamase production was found in
50% to 60% of H. influenzae and in >95% of M. catarrhalis.
BRO-1 isoform accounts for 88% of all beta-lactamase pro-
ducers of M. catarrhalis (16,35,36). Among amoxicillin-resis-
tant H. influenzae isolates, beta-lactamase nonproducers were
rare (<2%) (16). A continuing upsurge of H. influenzae iso-
lates resistant to macrolide (30%) and to trimethoprim-sul-
famethoxazole (50%) during the last decade has become
evident (16,35).
Enterobacteriaceae
The proportion of isolates of K. pneumoniae exhibiting the
ESBL phenotype has increased progressively from 3.4% in
1993 to 10.3% in 1997 in NTUH (37). Approximately one
fifth of the ESBL-producing K. pneumoniae were also resis-
tant to ciprofloxacin (37). From 1998 through 2000, several
reports from different hospitals showed that ESBL production
Figure. A, Macrolides consumption (grams x 1,000,000) in Taiwan and
the trends of erythromycin-resistant group A Streptococcus (EM-R
GAS), group B Streptococcus (EM-R GBS), and S. pneumoniae in
National Taiwan University Hospital from 1991 to 2000.  Macrolides
include intravenous and oral forms of erythromycin and oral forms of
clarithromycin, roxithromycin, and azithromycin. B,. Distribution of
erythromycin-resistant M-phenotype among isolates of streptococci.
Other streptococci include Groups C, F, and G, and viridans group
streptococci. Number in each bar indicates the percentage of erythro-
mycin-resistant isolates. Number above each bar indicates the percent-
age of M-phenotype among erythromycin-resistant isolates.
b
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accounts for 8% to 30% of clinical isolates of K. pneumoniae.
.Those producing SHV-5 and SHV-12 predominated. In addi-
tion, four novel beta-lactamases (CMY-8, SHV-25, SHV-26,
and IMP-8) were identified in 2000 in Taiwan (38-42). Among
the ESBL-producing E. coli isolates, which accounted for
1.6% to 6.7%, strains having CTX-M-3 and CMY-M-2 were
disseminated in Taiwan (39,43). In Taiwan, the previous belief
that characteristically susceptible strains (uniformly suscepti-
ble to cephalosporins) of K. pneumoniae caused primary liver
abscess, an endemic disease entity in patients with diabetes
mellitus, has now been disproved because two cephalosporin-
resistant K. pneumoniae strains causing primary liver abscess
have been found (44-46).
More than 40% of clinical isolates of nontyphoid Salmo-
nella species were resistant to multiple antibiotics (ampicillin,
chloramphenicol, and trimethoprim-sulfamethoxazole). Resis-
tance to cefotaxime and fluoroquinolones was estimated to be
low (1% to 3%) (47). 
P. aeruginosa, A. baumannii, and Other Bacteria
P. aeruginosa, A. baumannii, and other nonfermentative
gram-negative bacilli are usually resistant to various antimi-
crobial agents. A high proportion of clinical isolates, particu-
larly those recovered from patients in intensive-care units, that
are resistant to some last-line agents (ceftazidime, amikacin,
ciprofloxacin, and carbapenems) have now been found in Tai-
wan (3-6,48,49). A small outbreak of infections (three
patients) caused by a pan-drug-resistant P. aeruginosa (sero-
group O:4) clone in an intensive-care burn unit from April
1997 to May 1997 has been identified (3) This clone had been
isolated from a patient on the same unit 5 months before the
outbreak (3). Among P. aeruginosa isolates with reduced sus-
ceptibilities to imipenem, VIM-2 and VIM-3 are the predomi-
nant metallo-beta-lactamases (50). Furthermore, clonal
dissemination of VIM-3-producing P. aeruginosa has been
found among hospitals in Taiwan (50). Strains of ceftazidime-
and ciprofloxacin-resistant A. baumannii causing severe com-
munity-acquired pneumonia have emerged (49). Infections
caused by Chryseobacterium indologenes, a multidrug-resis-
tant nosocomial pathogen, appear to be another emerging
problem in Taiwan (5). Isolates of the Chryseobacterium
genus have remarkable discrepancies of susceptibility results
by the disk-diffusion and dilution method. Vancomycin is not
recommended as a drug of choice for treating C. meningosep-
ticum meningitis or other infections caused by Chryseobacte-
rium species because these isolates are highly resistant to
vancomycin when the standard agar dilution method is used (4).
Several multidrug-resistant (extended-spectrum cepha-
losporins, ciprofloxacin, or carbapenem resistance) Aeromo-
nas species have been reported (51,52). A derepressed mutant
of  A. hydrophila, which overexpresses beta-lactamases and
shows resistance to extended-spectrum cephalosporins, is used
if treatment with cefotaxime for Aeromonas bacteremia fails
(52). High prevalence of ciprofloxacin resistance for human
isolates of Campylobacter jejuni (52%) and C. coli (75%) may
be attributable to the widespread use of quinolones in poultry
in Taiwan (53,54). 
Strategy for Resistance Control in the 21st Century
By the end of the 20th century, many measures to control
resistance problems had been instituted in Taiwan. Antibiotics
had been removed from the list of available nonprescription
drugs at drugstores. Antibiotic interventions had been imple-
mented in many hospitals, particularly in intensive-care units,
to alleviate the high prevalence of resistance among nosoco-
mial pathogens. In 2000, the Council of Agriculture in Taiwan
prohibited the use of several antimicrobial agents (such as
avoparcin, kanamycin, kitasamycin, lasalocid, spiramycin,
salinomycin, and streptomycin), which had been widely used
as growth promoters or prophylactic agents in animal hus-
bandry in Taiwan during the past 2 to 3 decades, because they
may select for critical forms of resistance in human pathogens
in food-producing animals (54). Further research is ongoing to
reduce the risk for increasing resistance in human pathogens
caused by antibiotic use in animal husbandry. In the new mil-
lennium, the Center for Disease Control, Department of
Health, in Taiwan, has made control of antimicrobial resis-
tance a major goal. The two main tasks are to restrict use of
antibiotics for trivial upper respiratory tract infections and to
avoid inappropriate use of antibiotics for surgical prophylaxis. 
Acknowledgments
We thank the members of SMART (Surveillance for Multicenter
Antimicrobial Resistance in Taiwan), the Infectious Diseases Society
of the Republic of China, and the Society of Laboratory Medicine, the
Republic of China. The SMART members from 12 major hospitals in
Taiwan include Po-Ren Hsueh, Lee-Jene Teng, Kwen-Tay Luh,
Kwok-Woon Yu, Cheng-Yi Liu, Jang-Jih Lu, Feng-Yee Chang, Ting-I
Yang, Chun-Ming Lee, Tsu-Lan Wu, Hsieh-Shong Leu, Jainn-Ming
Shyr, Yeu-Jun Liu, Jen-Hsieh Wan, Jing-Jou Yang, Wen-Chien Ko,
Jiunn-Jong Wu, Yi-Chueh Yang, Yin-Ching Chuang, Chang-Fang
Peng, Kao-Pin Hwang, Wen-Kuei Huang, Yung-Ching Liu, and Li-
Shin Wang. 
Dr. Hsueh is assistant professor in the Departments of Laboratory
Medicine and Internal Medicine at National Taiwan University Col-
lege of Medicine in Taipei, Taiwan. His research interests include the
epidemiology of emerging and nosocomial infections and mecha-
nisms of antimicrobial drug resistance. He is actively involved in
developing a national research program for antimicrobial drug resis-
tance (Surveillance for Multicenter Antimicrobial Resistance in Tai-
wan-SMART).
References
  1. Ho M, McDonald C, Lauderdale TL, Yeh LLL, Chen PC, Shiau YR, et al.
Surveillance of antibiotic resistance in Taiwan, 1998. J Microbiol Immu-
nol Infect 1999;32:239-49.
  2. Chang SC, Hsieh WC. Current status of bacterial antibiotic resistance in
Taiwan. Journal of Infectious Diseases Society of the Republic of China
1996;7:83-8.SYNOPSIS
136 Emerging Infectious Diseases  •  Vol. 8, No. 2, February 2002
  3. Hsueh PR, Teng LJ, Yang PC, Chen YC, Ho SW, Luh KT. Persistence of
a multidrug-resistant Pseudomonas aeruginosa clone in an intensive care
burn unit. J Clin Microbiol 1998;36:1347-51.
  4. Chang JC, Hsueh PR, Wu JJ, Ho SW, Hsieh WC, Luh KT. Antimicrobial
susceptibility of flavobacteria as determined by agar dilution and disk dif-
fusion methods. Antimicrob Agents Chemother 1997;41:1301-6.
  5. Hsueh PR, Teng LJ, Yang PC, Ho SW, Hsieh WC, Luh KT. Increasing
incidence of nosocomial Chryseobacterium indologenes infections in Tai-
wan. Eur J Clin Microbiol Infect Dis 1997;16:568-74.
  6. Shi ZY, Liu PY, Lau YJ, Hu BS, Shir JM. Antimicrobial susceptibility of
clinical isolates of Acinetobacter baumannii. Diagn Microbiol Infect Dis
1996;24:81-5.
  7. National  Committee  for  Clinical  Laboratory Standards. Performance
standards for antimicrobial disk susceptibility tests. 6th ed. Approved
standard M2-A6. Wayne (PA): The Committee; 1998.
  8. Chang SC, Hsu LY, Luh KT, Hsieh WC. Methicillin-resistant Staphylo-
coccus aureus infections. J Formos Med Assoc 1988;87:157-63.
  9. Chen ML, Chang SC, Pan HJ, Hsueh PR, Yang LS, Ho SW, et al. Longi-
tudinal analysis of methicillin-resistant Staphylococcus aureus isolates at
a teaching hospital in Taiwan. J Formos Med Assoc 1999;98:426-32.
10. Hsueh PR, Chen HM, Lu YC, Wu JJ. Antimicrobial resistance and sero-
type distribution of Streptococcus pneumoniae strains isolated in southern
Taiwan. J Formos Med Assoc 1996;95:29-36.
11. Hsueh PR, Wu JJ, Hsiue TR. Invasive Streptococcus pneumoniae infec-
tion associated with rapidly fatal outcome in Taiwan. J Formos Med
Assoc 1996;95:364-71.
12. Chiou CC, Liu YC, Huang TS, Hwang WK, Wang JH, Lin HH, et al.
Extremely high prevalence of nasopharyngeal carriage of penicillin-resis-
tant Streptococcus pneumoniae among children in Kaohsiung, Taiwan. J
Clin Microbiol 1998;36:1933-7.
13. Hsueh PR, Teng LJ, Lee LN, Yang PC, Ho SW, Luh KT. Extremely high
incidence of macrolide and trimethoprim-sulfamethoxazole resistance
among clinical isolates of Streptococcus pneumoniae in Taiwan. J Clin
Microbiol 1999;37:897-901.
14. Hsueh PR, Teng LJ, Lee LN, Yang PC, Ho SW, Luh KT. Dissemination of
high-level penicillin-, extended-spectrum cephalosporin-, and erythromy-
cin-resistant Streptococcus pneumoniae clones in Taiwan. J Clin Micro-
biol 1999;37:221-4.
15. Fung CP, Hu BS, Lee SC, Liu PY, Jang TN, Leu HS, et al. Antimicrobial
resistance of Streptococcus pneumoniae isolated in Taiwan. An island-
wide surveillance study between 1996 and 1997. J Antimicrob
Chemother 2000;45:49-55.
16. Hsueh PR, Liu YC, Shyr JM, Wu TL, Yan JJ, Wu JJ, et al. Multicenter
surveillance of antimicrobial resistance of Streptococcus pneumoniae,
Haemophilus influenzae, and Moraxella catarrhalis in Taiwan during the
1998-1999 respiratory season. Antimicrob Agents Chemother
2000;44:1342-5.
17. Shi ZY, Enright MC, Wilkinson P, Griffiths D, Spratt BG. Identification of
three major clones of multiply antibiotic-resistant Streptococcus pneumo-
niae in Taiwanese hospitals by multilocus sequence typing. J Clin Micro-
biol 1998;36:3514-9.
18. Hsueh PR, Teng LJ, Wu TL, Ho SW, Luh KT. First clinical isolate of
Streptococcus pneumoniae exhibiting high-level resistance to fluoroqui-
nolones in Taiwan. J Antimicrob Chemother 2001;48:316-7.
19. Ben RJ, Lu JJ, Young TG, Chi WM, Wang CC, Chu ML, et al. Clinical
isolation of vancomycin-resistant Enterococcus faecalis in Taiwan. J For-
mos Med Assoc 1996;95:946-9.
20. Hsueh PR, Wu JJ, Lu JJ, Teng LJ, Luh KT. Antimicrobial susceptibilities
of clinical isolates of vancomycin-resistant enterococci in Taiwan. J For-
mos Med Assoc 1999;98:45-8.
21. Hsueh PR, Teng LJ, Pan HJ, Chen YC, Wang LH, Chang SC, et al. Emer-
gence of vancomycin-resistant enterococci at a university hospital in Tai-
wan: persistence of multiple species and multiple clones. Infect Control
Hosp Epidemiol 1999;20:828-33.
22. Hsueh PR, Liu YC, Yang D, Yan JJ, Wu TL, Huang WK, et al. Multi-
center surveillance of antimicrobial resistance of major bacterial patho-
gens in intensive care units in 2000 in Taiwan. Microb Drug Resist
2001;7:345-54.
23. Hsueh PR, Chen ML, Sun CC, Chen WH, Pan HJ, Yang LS, et al. Antimi-
crbial drug resistance in pathogens causing nosocomial infections at a
University Hospital in Tiawan, 1981-1999. Emerg Infect Dis 2002;8:63-
8.
24. Lu JJ, Perng CL, Ho MF, Chiueh TS, Lee WH. High prevalence of vanB2
vancomycin resistant Enterococcus faecium in Taiwan. J Clin Microbiol
2001;39:2140-5.
25. Luh KT, Hsueh PR, Teng LJ, Pan HJ, Chen YC, Lu JJ, et al. Quinupristin-
dalfopristin resistance among gram-positive bacteria in Taiwan. Antimi-
crob Agents Chemother 2000;44:3374-80.
26. Hsueh PR, Chen HM, Huang AH, Wu JJ. Decreased activity of erythro-
mycin against Streptococcus pyogenes in Taiwan. Antimicrob Agents
Chemother 1995;39:2239-42.
27. Wu JJ, Lin KY, Hsueh PR, Liu JW, Pan HI, Sheu S. High incidence of
erythromycin-resistant streptococci in Taiwan. Antimicrob Agents
Chemother 1997;41:844-6.
28. Yan JJ, Wu HM, Huang AH, Fu HM, Lee CT, Wu JJ. Prevalence of poly-
clonal mefA-containing isolates among erythromycin-resistant group A
streptococci in southern Taiwan. J Clin Microbiol 2000;38:2475-9.
29. Hsueh PR, Teng LJ, Lee LN, Yang PC, Ho SW, Lue HC, et al. Extremely
high proportion and substantial upsurge in incidence of erythromycin-
resistant M phenotype in Streptococcus pyogenes but not in Streptococcus
pneumoniae isolates collected over a 15-year period in Taiwan. Microb
Drug Resist. In press 2001.
30. Hsueh PR, Teng LJ, Lee LN, Ho SW, Yang PC, Luh KT. A high incidence
of erythromycin resistance among clinical isolates of Streptococcus aga-
lactiae in Taiwan. Antimicrob Agents Chemother 2001;45:3205-8.
31. Teng LJ, Hsueh PR, Chen YC, Ho SW, Luh KT. Antimicrobial suscepti-
bility of viridans group streptococci in Taiwan with an emphasis on the
high rates of resistance to penicillin and macrolides in Streptococcus ora-
lis. J Antimicrob Chemother 1998;41:621-7.
32. Department of Health, The Executive Yuan ROC. TB statistics-1998.
general health statistics 1998. Taipei:Republic of China; 1998. p. 10-11.
33. Chiang IH, Yu MC, Bai KJ, Wu MP, Hsu CJ, Lin TP, et al. Drug resis-
tance patterns of tuberculosis in Taiwan. J Formos Med Assoc
1998;97:581-3.
34. Chen MK, Wang CC, Chu ML, Pan TM. Prospective surveillance of chil-
dren with invasive Haemophilus influenzae disease in Taiwan. J Micro-
biol Immunol Infect 1999;32:257-60.
35. Lin HC, Wang CC, Yu CM, Chu ML. Prevalence of antimicrobial resis-
tance among clinical isolates of Haemophilus influenzae in Taiwan. J For-
mos Med Assoc 1999;98:319-25.
36. Fung CP, Lee SC, Liu YF, Jang TN, Wong FD, Kuo BI, et al. Beta-lactam
resistance and beta-lactamase isoforms of Moraxella catarrhalis isolates
in Taiwan. J Formos Med Assoc 1998;97:453-7.
37. Jan IS, Hsueh PR, Teng LJ, Ho SW, Luh KT. Antimicrobial susceptibility
testing for Klebsiella pneumoniae isolates resistant to extended-spectrum
ß-lactam antibiotics. J Formos Med Assoc 1998;97:661-6. 
38. Liu PY, Tung JC, Ke SC, Chen SL. Molecular epidemiology of extended-
spectrum beta-lactamase-producing Klebsiella pneumoniae isolates in a
district hospital in Taiwan. J Clin Microbiol 1998;36:2759-62.
39. Siu LK, Lu PL, Hsueh PR, Lin FM, Chang SC, Luh KT, et al. Bacteremia
due to extended-spectrum b-lactamase-producing Escherichia coli and
Klebsiella pneumoniae in a pediatric oncology ward: clinical features and
identification of different plasmids carrying both SHV-5 and TEM-1
genes. J Clin Microbiol 1999;37:4020-7.
40. Yan JJ, Wu SM, Tsai SH, Wu JJ, Su IJ. Prevalence of SHV-12 among
clinical isolates of Klebsiella pneumoniae producing extended-spectrum
ß-lactamase and identification of a novel AmpC enzyme (CMY-8) in
southern Taiwan. Antimicrob Agents Chemother 2000;44:1438-42.Emerging Infectious Diseases  •  Vol. 8, No. 2, February 2002 137
SYNOPSIS
	




41. Chang FY, Siu LK, Fung CP, Huang MH, Ho M. Diversity of SHV and
TEMb-lactamases in Klebsiella pneumoniae: gene evolution in northern
Taiwan and two novel beta-lactamases, SHV-25 and SHV-26. Antimicrob
Agents Chemother 2001;45:2407-13.
42. Yan JJ, Ko WC, Wu JJ. Identification of a plasmid encoding SHV-12,
TEM-1, and a variant of IMP-2 metallo-beta-lactamase, IMP-8, from a
clinical isolate of Klebsiella pneumoniae. Antimicrob Agents Chemother
2001;45:2368-71.
43. Yan JJ, Ko WC, Tsai SH, Wu HM, Lin YT, Wu JJ. Dissemination of
CTX-M-3 and CMY-2 beta-lactamases among clinical isolates of Escher-
ichia coli in southern Taiwan. J Clin Microbiol 2000;38:4320-5.
44. Wang JH, Liu YC, Lee SSJ, Yen MY, Chen YS, Wang JH, et al. Primary
liver abscess due to Klebsiella pneumoniae in Taiwan. Clin Infect Dis
1998;26:1434-8.
45. Fung CP, Hu BS, Chang FY, Lee SC, Kuo BI, Ho M, et al. A 5-year study
of the seroepidemiology of Klebsiella pneumoniae: high prevalence of
capsular serotype K1 in Taiwan and implication for vaccine efficacy. J
Infect Dis 2000;181:2075-9.
46. Hsueh PR, Teng LJ, Chen YC, Luh KT. Primary liver abscess caused by
one clone of Klebsiella pneumoniae with two colonial morphotypes and
resistotypes. Emerg Infect Dis 2002;8:100-5.
47. Su LH, Chiu CH, Kuo AJ, Chia JH, Sun CF, Leu HS, et al. Secular trends
in incidence and antimicrobial resistance among clinical isolates of Sal-
monella at a university hospital in Taiwan, 1993-1999. Epidemiol Infect.
2001;127:207-13.
48. Liu PYF, Lau YJ, Hu BS, Shyr JM, Shi ZY, Tsai WS, et al. Comparison of
susceptibility to extended-spectrum beta-lactam antibiotics and ciproflox-
acin among gram-negative bacilli isolated from intensive care units.
Diagn Microbiol Infect Dis 1995;22:285-91.
49. Chen ML, Hsueh PR, Lee LN, Yu CJ, Yang PC, Luh KT. Severe commu-
nity-acquired pneumonia due to Acinetobacter baumannii. Chest 2001;
120: 1072-7.
50. Yan JJ, Hsueh PR, Ko WC, Luh KT, Tsai SH, Wu HM, et al. Metallo-
beta-lactamases among clinical isolates of Pseudomonas in Taiwan and
identification of VIM-3, a novel variant of the VIM-2 enzyme. Antimi-
crob Agents Chemother 2001;45:2224-8.
51. Ko WC, Yu KW, Liu CY, Huang CT, Leu HS, Chuang YC. Increasing
antibiotic resistance in clinical isolates of Aeromonas strains in Taiwan.
Antimicrob Agents Chemother 1996;40:1260-2.
52. Ko WC, Wu HM, Chang TC, Yan JJ, Wu JJ. Inducible beta-lactam resis-
tance in Aeromonas hydrophila: therapeutic challenge for antimicrobial
therapy. J Clin Microbiol 1998;36:3188-92.
53. Li CC, Chiu CH, Wu JL, Huang YC, Lin TY. Antimicrobial susceptibility
of Campylobacter jejuni and coli by using E-Test in Taiwan. Scand J
Infect Dis 1998;30:39-42.
54. McDonald LC, Chen MT, Lauderdale TL, Ho M. The use of antibiotics
critical to human medicine in food-producing animals in Taiwan. J Micro-
biol Immunol Infect 2001;34:97-102.
Address for correspondence: Kwen-Tay Luh, Department of Laboratory Med-
icine, National Taiwan University Hospital, No. 7 Chung-Shan Road, Taipei
100, Taiwan; fax: 886-2-2322-4263; e-mail: luhkt@ha.mc.ntu.edu.tw
Please print your name and business 
address in the box and return by fax 
to 404-371-5449 or mail to
EID Editor
CDC/NCID/MS D61
1600 Clifton Road, NE
Atlanta, GA 30333
Moving? Please give us your new address (in the box) and print the number of your old mailing
label here______________
YES, I would like to receive Emerging Infectious Diseases.
The print journal is available at no charge to public health professionals